United States - English - NLM (National Library of Medicine)

physicians total care, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - amlodipine 10 mg - exforge hct (amlodipine, valsartan, hydrochlorothiazide) is indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension [see dosage and administration (2)]. because of the hydrochlorothiazide component, exforge hct is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. pregnancy category d valsartan, like other drugs that act on the renin angiotensin system, can cause fetal and neonatal morbidity and death when used during the second or third trimester of pregnancy. if exforge hct is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. angiotensin ii receptor antagonists, like valsartan, and angiotensin converting enzyme (ace) inhibitors exert similar effects on the renin-angiotensin system. in several dozen published cases, ace inhibitor use during the second and third trimesters of pregnancy was as

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/160/12.5 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/160/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/320/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 5/160/12.5 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 5/160/25 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - amlodipine 5 mg - amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine and the angiotensin ii receptor blocker (arb) class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with amlodipine and valsartan tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education prog

United States - English - NLM (National Library of Medicine)

rising health, llc - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 2.5 mg - amlodipine and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), angiotensin-converting enzyme (ace) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. - amlodipine and benazepril hydrochloride capsules  are contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules. - amlodipine and benazepril hydrochloride capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan [see warnings a

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 2.5 mg - amlodipine and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), angiotensin-converting enzyme (ace) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. - amlodipine and benazepril hydrochloride capsules  are contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules. - amlodipine and benazepril hydrochloride capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan [see warnings a

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - valsartan 320 mg - valsartan tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. there are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, d